Abstract
[Extract]
To the Editor—In his editorial, Monto [1] discusses the evidence from randomized trials and observational studies regarding the efficacy of neuraminidase inhibitors. With respect to the observational evidence, Monto argues that “the supporting evidence increases”. However Monto’s discussion of observational studies of H1N1 2009 only references manufacturer-funded research. Publicly funded (and unfunded) studies [2–4], including ours [2], have come to different conclusions, but these were not cited. We believe readers should be made aware of these omissions.
To the Editor—In his editorial, Monto [1] discusses the evidence from randomized trials and observational studies regarding the efficacy of neuraminidase inhibitors. With respect to the observational evidence, Monto argues that “the supporting evidence increases”. However Monto’s discussion of observational studies of H1N1 2009 only references manufacturer-funded research. Publicly funded (and unfunded) studies [2–4], including ours [2], have come to different conclusions, but these were not cited. We believe readers should be made aware of these omissions.
Original language | English |
---|---|
Pages (from-to) | 1578-1579 |
Number of pages | 2 |
Journal | The Journal of infectious diseases |
Volume | 222 |
Issue number | 9 |
DOIs | |
Publication status | Published - 1 Nov 2020 |